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aDepartment of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, London,
United Kingdom
ABSTRACT Chagasic heart disease develops in 30% of those infected with the pro-
tozoan parasite Trypanosoma cruzi, but can take decades to become symptomatic.
Because of this, it has been difﬁcult to assess the extent to which antiparasitic ther-
apy can prevent the development of pathology. We sought to address this question
using experimental murine models, exploiting highly sensitive bioluminescent imag-
ing to monitor curative efﬁcacy. Mice were inoculated with bioluminescent parasites
and then cured in either the acute or chronic stage of infection with benznidazole.
At the experimental endpoint (5 to 6 months postinfection), heart tissue was re-
moved and assessed for inﬂammation and ﬁbrosis, two widely used markers of car-
diac pathology. Infection of BALB/c and C3H/HeN mice with distinct T. cruzi lineages
resulted in greatly increased myocardial collagen content at a group level, indicative
of ﬁbrotic pathology. When mice were cured by benznidazole in the acute stage,
the development of pathology was completely blocked. However, if treatment was
delayed until the chronic stage, cardiac ﬁbrosis was observed in the BALB/c model,
although the protective effect was maintained in the case of C3H/HeN mice. These
experiments therefore demonstrate that curative benznidazole treatment early in
murine T. cruzi infections can prevent the development of cardiac ﬁbrosis. They also
show that treatment during the chronic stage can block pathology but the effective-
ness varies between infection models. If these ﬁndings are extendable to humans, it
implies that widespread chemotherapeutic intervention targeted at early-stage infec-
tions could play a crucial role in reducing Chagas disease morbidity at a population
level.
KEYWORDS Chagas disease, benznidazole, cardiac pathology, experimental model
Chagas disease results from infection with the protozoan parasite Trypanosoma cruzi,and it is an important public health problem throughout Latin America (1, 2). A
total of 5 to 8 million people are infected, mainly in poor rural areas. Hematophagous
triatomine bugs are the principal route of transmission, although contaminated food
and drink, blood transfusion, and the congenital route are also important. As a result of
migration, many cases of Chagas disease are now being diagnosed outside regions
where it is endemic, particularly in the United States and Europe (3, 4).
T. cruzi is an obligate intracellular parasite and can infect most nucleated cells.
During the acute stage of the disease (2 to 8 weeks postinfection in humans), parasites
become widely disseminated in tissues and organs and can be detected in the
bloodstream. In the majority of cases, the acute stage results in a mild febrile illness.
Occasionally, particularly in children, the outcomes can be more serious, and some-
times fatal, due to myocarditis or meningoencephalitis. In most individuals, the infec-
tion is controlled by the adaptive immune response driven by CD8 IFN- T cells (5,
6), and the disease then progresses to an asymptomatic chronic stage, which is
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characterized by an extremely low parasite burden. However, over time (sometimes
decades), 30% of those infected develop pathology, which can manifest as cardiomy-
opathy and sudden heart failure (7–9). In addition, about 10% develop digestive tract
megasyndromes, symptoms that sometimes overlap with the cardiac complications.
The nitroheterocyclic drugs benznidazole and nifurtimox have been used to treat
Chagas disease for more than 50 years (10, 11). However, they have a range of side
effects and require extended dosing (60 to 90 days) (12–14). As a result, compliance is
a problem and treatment failure is common. There is also potential for cross-resistance,
since both drugs require bioactivation within the parasite by the mitochondrial nitrore-
ductase TcNTR-1 (15, 16). Despite these issues, clinical trials have demonstrated that
parasitological cure is achievable in both the acute and chronic stages (12, 13, 17, 18).
However, the capacity of curative drugs to prevent or alleviate cardiac pathology is
unresolved. Addressing this question is one of the major challenges in the Chagas
disease ﬁeld.
Cardiomyopathy in chronic Chagas disease is associated with inﬂammation, ﬁbrosis,
thromboembolism, ventricular arrhythmia, and progressive cardiac failure (19, 20). The
mechanisms that drive pathology have been the subject of vigorous debate focused on
the central question of whether parasite persistence is required. There has been a
long-standing hypothesis that autoimmunity has a crucial role. This is based on
numerous reports of cross-reactivity between epitopes in host and parasite proteins,
the rapid polyclonal expansion of B and T cells during the acute stage, including some
that are autoreactive (21, 22), and the inability to consistently detect parasites in
chagasic hearts. Resolving the importance of parasite persistence in humans is complex
because of the long period over which chronic pathology develops and the highly
diverse nature of the disease. Furthermore, factors such as host and parasite genetics
and immune status are also thought to have a crucial inﬂuence (23). Identifying the
underlying mechanisms responsible for pathology has major implications for the
management and treatment of chronic T. cruzi infections.
In the absence of robust experimental systems for investigating pathogenesis in
humans, predictive animal models have an important role in Chagas disease research.
Several mouse models are available that display symptoms analogous to those in
humans, particularly in terms of cardiac pathology. However, practical difﬁculties in
detecting the extremely low numbers of parasites in the chronic stage have compli-
cated the establishment of a deﬁnitive link between curative treatment and the
prevention of clinical disease. Recently, highly sensitive in vivo bioluminescence imag-
ing applicable to chronic murine infections has provided an improved framework for
addressing this question (24, 25). Studies have revealed that parasites are readily
detectable in most organs and tissues during the acute stage (24, 26). As the infection
proceeds, the adaptive immune response then reduces the parasite burden by up to 3
orders of magnitude, although the infection is not eliminated. The gastrointestinal (GI)
tract is the major parasite reservoir during the chronic stage, with infection of other
organs being sporadic and inﬂuenced by host and parasite genetics. These observa-
tions are consistent with a model in which the gut provides an immunotolerant niche
that permits long-term maintenance of the infection, with intermittent trafﬁcking of
parasites or parasite-infected cells to other sites (27). Crucially, cardiac damage in these
mice was detectable in the absence of locally persistent infection (24, 26). This implies
that episodic infections of the heart may give rise to localized immune responses that
clear the parasite, but which result in cumulative tissue damage.
There is now a general view that the presence of the parasite is required for the
development of chagasic heart disease (28). If correct, this suggests that curative drug
treatment should have a beneﬁcial outcome in terms of pathology. Several recent
reports focused on acute stage murine infections seem to support this (29–33). With
chronic-stage infections the data are less clear-cut (34), in part because it is difﬁcult to
conﬁrm parasitological cure, even with PCR-based methodologies. In humans, the
BENEFIT trial reported no obvious improvements in cardiomyopathy-related clinical
outcomes 5 years after chronic stage infections were treated with benznidazole (17).
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However, since patients for this study were selected on the basis of preexisting
cardiomyopathy, it has not been possible to extrapolate the ﬁndings to the majority of
chronically infected individuals, who are asymptomatic.
New information on the extent to which parasitological cure impacts on the
progression of heart pathology is crucial for informing the international effort aimed at
developing new drugs against Chagas disease. Here, we have exploited predictive
murine models and highly sensitive bioluminescence imaging to monitor curative
treatment at various stages of the disease cycle and to assess the outcomes in terms of
cardiac pathology.
RESULTS
Our aim was to investigate if treatment with curative doses of benznidazole pre-
vented or alleviated the development of chagasic cardiac damage in mice by assessing
myocarditis and myocardial ﬁbrosis, widely used quantiﬁable markers of pathology. To
reﬂect the genetic diversity of T. cruzi, we selected strains JR (discrete typing unit [DTU]
I) and CL Brener (DTU VI), both of which were modiﬁed to express a red-shifted
luciferase (24, 26). Following inoculation into the peritoneal cavity, the limit of detec-
tion with this highly sensitive system is close to 100 parasites, and there is a strong
correlation between total body bioluminescence and parasite burden (24). Two infec-
tion combinations were investigated, strain JR in C3H/HeN mice (JR-C3H) and strain CL
Brener in BALB/c mice (CL-BALB/c). Previously, we have shown that chronic infections
in these models give rise to signiﬁcant pathological ﬁbrosis, which is particularly severe
in the case of the JR-C3H combination, although endpoint cardiac inﬂammation tends
to be mild or negligible (24, 26). To initiate infections, mice were inoculated intraperi-
toneally (i.p.) with 1  103 T. cruzi bloodstream trypomastigotes. At various time points
postinfection, they were treated with benznidazole at 100 mg/kg for 20 days (35), a
regimen that cures both acute and chronic infections (Fig. 1 and 2).
Curative benznidazole treatment of infected C3H mice was initiated during the
acute stage (day 14) or after transition to the chronic phase (day 73) (Fig. 1A). Mice were
then monitored by in vivo imaging until the experimental endpoint (days 150 to 153).
In nontreated mice, the infection reached a peak approximately 21 days postinfection.
This was followed by progressive reduction in the parasite burden until the infection
entered the chronic stage (days 50 to 60), when levels were up to three orders of
magnitude lower (Fig. 1B). The chronic stage is characterized by the presence of highly
dynamic bioluminescent foci that are detectable by in vivo imaging (26). When the
internal organs were examined by ex vivo imaging, bioluminescent foci were also
detectable in the colon and/or stomach in all cases and sporadically in other organs,
including the heart (Fig. 1C). In the JR-C3H model, infection foci were observed more
frequently in non-GI tract sites than was the case in other parasite/mouse strain
combinations (26), although there was no speciﬁc tropism for the heart.
To evaluate the capacity of curative treatment (Fig. 1B and C) to prevent pathology,
quantitative analysis of inﬂammation and ﬁbrosis was performed on cardiac muscle
obtained 150 to 153 days postinfection. There was a slight increase in myocardium
cellularity in nontreated infected C3H mice compared to age-matched noninfected,
nontreated controls, although this was just below the level of signiﬁcance (P  0.13)
(Fig. 3A and B). No parasites were detected in any cardiac images from nontreated
animals (360 examined), although bioluminescence signals suggested low-level in-
fections in some mice (Fig. 1C). Exposure to benznidazole in the absence of infection
did not cause myocarditis (Fig. 3A). In mice cured in either the acute or chronic stage
of infection, cardiac inﬂammation was similar to that in the noninfected controls and
displayed no signiﬁcant correlation with ﬁbrosis at the level of individual mice (below).
We used collagen content as an indicator of pathological cardiac ﬁbrosis (see
Materials and Methods). Baseline levels in noninfected control mice displayed consid-
erable uniformity, with no signiﬁcant differences between benznidazole-treated and
nontreated animals (Fig. 3C and D). In contrast, in nontreated infected mice, there was
remarkable variation, with differences of more than 5-fold in the extent of ﬁbrosis
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within the cohort (24 mice, 15 cardiac images examined per individual). At a group
average level, cardiac collagen was more than 2-fold higher in the nontreated infected
mice than in the noninfected mice (P  0.0006). However, within this group compar-
ison, approximately half of the JR-infected mice exhibited no evidence of ﬁbrosis,
whereas the other half displayed major increases in collagen content (Fig. 3C). When
C3H mice that had been cured of T. cruzi infection with benznidazole were evaluated
at the experimental endpoint (day 150 to 153), the myocardial collagen content was
found to be considerably lower than in the noncured group (treatment initiation on day
14, P  0.008; on day 73, P  0.03) and not signiﬁcantly different from that in
noninfected mice (Fig. 3C and D). These data therefore suggest that in the JR-C3H
model, curative drug treatment in either the acute or chronic stage of infection can
prevent the development of cardiac ﬁbrosis.
When the CL-BALB/c parasite-mouse combination was used to further examine the
effect of curative drug-treatment (Fig. 2B and C) on chronic cardiac pathology, we
included additional treatment time points in the acute and chronic stages (Fig. 2A). In
this model, the acute-stage parasite burden peaks at day 14 postinfection, but the
subsequent proﬁle of parasite infection is otherwise generally similar to that in the
JR-C3H combination. In line with previous results (26), we observed that during BALB/c
chronic stage infections, CL Brener parasites were more tightly restricted to the GI tract
than was the case with JR infections of C3H mice (Fig. 1C and 2C). Histopathological
analysis of cardiac tissue from nontreated CL Brener-infected BALB/c mice (days 156 to
169 postinfection) revealed signiﬁcant diffuse cellular inﬁltration compared to that in
noninfected controls (Fig. 4A and B) (P  0.005). Inﬂammatory inﬁltrates were com-
prised predominantly of mononuclear cells with lymphocytic morphology. Similarly, an
increase in inﬂammatory inﬁltration was observed in mice that had been cured with
FIG 1 Benznidazole treatment in both the acute and chronic stage cures C3H/HeN mice infected with T. cruzi JR strain. (A) Outline of infection and treatment
schedule. Mice were treated with 100 mg/kg benznidazole once daily by the oral route for 20 days (Materials and Methods). (B) Representative ventral in vivo
images of treated (starting day 14 or 73) and nontreated mice at sequential time points postinfection. All images use the same log10-scale heat-map with
minimum and maximum radiance values as indicated. (C) Ex vivo bioluminescence images of organs and tissues taken at 152 days postinfection (dpi). Organs
arranged as shown (upper image).
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benznidazole during the acute stage (treatment starting day 14 or 22; P  0.0004 and
P  0.005, respectively). Mice that were cured during the chronic stage showed some
signs of myocarditis, but inﬁltrates were less intense and below the level of signiﬁcance
(treatment starting days 66 and 110; P  0.26 and P  0.44, respectively).
In nontreated BALB/c mice infected with CL Brener, we found a signiﬁcant increase in
ﬁbrosis compared to that of age-matched noninfected controls (Fig. 4C and D) (P 0.007)
when cardiac sections were examined at the experimental endpoint. However, as with the
JR-C3H combination, there was considerable variation in the extent of ﬁbrosis following
infection and only a minor or negligible correlation with inﬂammation (Fig. 4E). In both
models, collagen deposits were diffusely distributed within the muscle ﬁbers and interstitial
spaces, although in the JR-C3H combination, ﬁbrosis was more often present as dense focal
deposits organized between muscle ﬁbers. This intense ﬁbrosis in the interstitial spaces
produced larger gaps between muscle ﬁbers. No differences in inﬂammation or ﬁbrosis
between atrial and ventricular regions of the heart were apparent. When cardiac sections
from mice cured in the acute stage (treatment starting day 14 or 22) were examined on
days 156 to 169, there was no evidence of ﬁbrosis, as the level of collagen was considerably
less than that in the nontreated cohort (Fig. 4C) (P 0.0017 and P 0.0002, respectively).
Levels were the same as those in the noninfected controls, a pattern similar to that in the
JR-C3H combination (Fig. 3C). However, in samples taken from mice treated in the chronic
stage, cumulative ﬁbrosis was apparent. The collagen content was signiﬁcantly greater in
mice where treatment was initiated on day 110 (P 0.009), similar to that in noncuredmice
(Fig. 4C). When treatment began on day 66, several of the mice exhibited ﬁbrosis at the
experimental endpoint, although this increased collagen content did not reach the level of
signiﬁcance at a group level (P 0.30). Therefore, in the CL-BALB/c experimental model, the
timing of curative treatment during an infection is crucial for preventing cardiac pathology.
DISCUSSION
Chagas disease drug discovery programs are predicated on the assumption that
antiparasitic therapy can prevent or reduce the development of chronic pathology. The
target group for these drugs is the 5 to 8 million individuals in the asymptomatic
chronic phase of the disease, since the vast majority of acute-stage infections pass
undetected and patients with advanced symptoms are unlikely to beneﬁt (17). Increas-
FIG 2 Benznidazole treatment in both the acute and chronic stage cures BALB/c mice infected with T. cruzi strain CL Brener. (A) Outline of infection and
treatment schedule. Mice were treated with 100 mg/kg benznidazole once daily by the oral route for 20 days (see Materials and Methods). (B) Representative
ventral in vivo images of treated (starting day 14, 66, or 110) and nontreated mice at sequential time points postinfection. (C) Ex vivo bioluminescence images
of organs and tissues taken at 169 days postinfection (dpi). Organs arranged as shown in Fig. 1C.
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ing evidence suggests that parasite persistence is a prerequisite for cardiac pathology
(27, 28, 36, 37), providing a theoretical rationale for curative therapy. Despite this, it has
been problematic to conﬁrm beneﬁcial outcomes in humans (17). Predictive experi-
mental models are therefore of particular importance. However, even in mice, studies
into the effectiveness of antiparasitic treatment have been confounded by a general
inability to monitor infections during the chronic stage and by difﬁculties in demon-
strating sterile cure.
In the current work, we exploited highly sensitive bioluminescent imaging to
conﬁrm antiparasitic drug efﬁcacy (Fig. 1C and 2C). First, we assessed the capacity of
benznidazole to prevent pathology in the JR-C3H parasite-host combination. Previous
studies revealed considerable variation in the severity of cardiac ﬁbrosis during chronic
infections in this model (26). Large cohort sizes were therefore used to provide
statistical power. As expected, we found extensive differences in the level of collagen
FIG 3 Curative benznidazole treatment of C3H/HeN mice infected with T. cruzi strain JR prevents the development of cardiac ﬁbrosis. Infected mice (see
Materials and Methods) were either nontreated (NT; n  24), or treated (T) with benznidazole for 20 days, as outlined in the legend to Fig. 1, commencing day
14 postinfection (n  10), or day 73 (n  12). Groups of noninfected mice, either nontreated (NT; n  16), or treated (T) (starting on day 14, n  8, or on day
73, n  8) were run in parallel. Cardiac tissue was harvested (day 150 to 153) and assessed for inﬂammation and ﬁbrosis (see Materials and Methods). (A)
Quantitative histopathological analysis of inﬂammation. The number of nuclei per 6  104 m2 was quantiﬁed as a cellular myocarditis index. Data are shown
as mean standard deviation. Inﬂammation in nontreated infected mice was slightly but signiﬁcantly greater than that in noninfected controls or in drug cured
mice. (B) Representative myocardial sections stained with H&E and used to assess inﬂammation. (C) Quantiﬁcation of collagen content (blue area in Masson’s
trichrome-stained sections) as a marker of cardiac ﬁbrosis (see the text for more details and Materials and Methods for description of statistical procedures).
(D) Masson’s trichrome-stained photomicrographs demonstrating ﬁbrosis in mice heart sections. In panels B and D, the magniﬁcation is 400. Bar, 30 m.
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deposition in the heart muscle of infected nontreated mice (Fig. 3C and D). This
heterogeneity is typical of cardiac pathology in humans during chronic Chagas disease.
Intriguingly, curative treatment during both the acute and chronic stage of infection
completely blocked the development of ﬁbrosis. We then used the CL-BALB/c combi-
nation, and we included additional experimental time points to better assess the
protective effect. In this model, chronic infection also led to signiﬁcantly increased
ﬁbrosis in the untreated mice (Fig. 4C and D), and antiparasitic treatment during the
acute stage (starting days 14 or 22) prevented pathological collagen deposition in
cardiac muscle. However, if treatment was delayed until the chronic stage (starting day
110), high levels of ﬁbrosis were observed, similar in severity to those in nontreated
mice.
In murine models of chronic Chagas disease, the GI tract is the major site of parasite
persistence (25, 26), with sporadic infection of the heart and other organs (e.g., Fig. 1C
and 2C). The heart does not appear to be preferentially infected, and ﬁbrosis can
develop in the absence of cardiac-localized parasite persistence. We have proposed
that pathology arises from collateral damage resulting from immune responses trig-
gered by long-term, intermittent reinvasion of the heart by parasites derived from more
permissive niches, which may include the GI tract (27). In both mice and humans, this
dynamic process could contribute to the heterogeneous and cumulative nature of
pathology, with the low regenerative capacity of cardiac muscle (38) accounting for the
organ-speciﬁc damage.
The major ﬁnding of our current study is that curative treatment can prevent cardiac
ﬁbrosis. In the case of the CL-BALB/c model, this requires treatment earlier in the
infection, whereas with the JR-C3H combination, treatment can be postponed until at
FIG 4 Curative benznidazole therapy prevents the development of cardiac ﬁbrosis in BALB/c mice infected with T. cruzi CL Brener when treatment is initiated
in the acute stage but not when initiated in the chronic stage. Infected mice were either nontreated (NT; n  19), or treated (T) with benznidazole for 20 days,
as outlined in the legend to Fig. 2, commencing day 14 postinfection (n  10), day 22 (n  12), day 66 (n  12), or day 110 (n  12). Groups of noninfected
mice, either nontreated (NT; n 7), or treated (T) (starting on day 66, n 4, or on day 110, n 4) were run in parallel. Cardiac tissue was harvested and assessed
for inﬂammation and ﬁbrosis (see Materials and Methods). (A) Quantitative histopathological analysis of inﬂammation. The number of nuclei per 6  104 m2
was quantiﬁed as a myocarditis index. Data are shown as mean  standard deviation. (B) Representative myocardial sections stained with H&E demonstrating
inﬂammation. (C) Quantiﬁcation of collagen content (blue area in Masson’s trichrome-stained sections) as a marker of cardiac ﬁbrosis. (D) Masson’s
trichrome-stained photomicrographs demonstrating ﬁbrosis in mice heart sections. In panels B and D, the magniﬁcation is 400. Bar, 30 m. (E) Pearson
correlation analysis of myocarditis against cardiac ﬁbrosis scores. Data are from samples obtained at 169 days postinfection from the groups shown in panels
A and C.
Antiparasitic Drugs and Chagas Disease Pathology Antimicrobial Agents and Chemotherapy
October 2018 Volume 62 Issue 10 e00832-18 aac.asm.org 7
least day 73 without compromising the protective effect. This disparity could reﬂect
temporal variations in the infection proﬁle between the two models, the type of
localized immune response, parasite diversity, or a combination of all three. It would be
premature at this stage to extrapolate these differences and to deﬁne them as
representative of speciﬁc parasite lineages. In the case of myocarditis, there was not a
signiﬁcant association with infection in the JR-C3H model (Fig. 3). Although this was
more pronounced in the CL-BALB/c combination, there was no positive correlation
between endpoint inﬂammation and ﬁbrosis at the level of individual mice (Fig. 4E).
This is perhaps unsurprising given the episodic character of active heart parasitism and
snapshot nature of the endpoint analysis. We have observed this lack of association
previously and found that it is the inability to restrict infection to the gut during chronic
infections that best correlates with heart disease severity (26).
The ﬁndings reported here demonstrate that antiparasitic treatment can prevent
cardiac damage, and that T. cruzi persistence, even when not continuous in the heart,
is a major determinant of ﬁbrosis. Of particular signiﬁcance, is our ﬁnding in the
CL-BALB/c model that delays in administering curative treatment can have detrimental
effects on disease outcome, suggesting that pathology is cumulative in the presence of
infection. Our hypothesis is that pathology results from collateral damage caused by
the localized immune responses that eradicate the intermittent cardiac infections
during the chronic stage. The apparent stochastic nature of these infections may
contribute to the diversity of pathological outcomes, although other factors are almost
certainly involved. In this context, we tried to capture some of the potential variation
in disease outcome attributable to host:parasite strain differences by using the T. cruzi
CL Brener (DTU VI) and JR (DTU I) isolates, and the BALB/c and C3H/HeN mouse strains.
More detailed studies in this area are clearly warranted to further dissect the effect of
host and parasite diversity on disease pathology.
If the results reported here are applicable to humans, they strongly support a policy
of early treatment of individuals who are seropositive for T. cruzi, but asymptomatic.
This could prevent the time-dependent build-up of largely irreversible cardiac damage.
At present, up to 99% of asymptomatic people infected with T. cruzi are unaware of
their condition (39). Therefore, population-wide diagnostic programs should be con-
sidered a public health priority in areas where Chagas disease is endemic, particularly
as more effective drugs become available.
MATERIALS AND METHODS
Parasites. Bioluminescent T. cruzi strains (CL Brener and JR) that constitutively express the red-
shifted luciferase PpyRE9h (40) were generated and cultured as described previously (24, 26). Metacyclic
trypomastigotes were produced by transfer to supplemented Grace’s medium (41) and harvested after
4 to 7 days. Tissue culture trypomastigotes were obtained from infected L6 rat myoblasts (26).
Murine infections and bioluminescence imaging. Animal work was performed under United
Kingdom Home Ofﬁce project licenses (PPLs 70/6997 and 70/8207) and approved by the LSHTM Animal
Welfare and Ethical Review Board. Procedures were conducted in accordance with the United Kingdom
Animals (Scientiﬁc Procedures) Act 1986 (ASPA). BALB/c and C3H/HeN mice were purchased from Charles
River (UK), and CB17 SCID mice were bred in-house. Animals were maintained under speciﬁc pathogen-
free conditions in individually ventilated cages. They experienced a 12-h light/dark cycle, with access to
food and water ad libitum. SCID mice were infected with 1  104 bloodstream trypomastigotes (BTs) in
0.2 ml phosphate-buffered saline (PBS) via i.p. injection. BALB/c and C3H female mice (aged 7 to 8 weeks)
were infected by i.p. injection of 1 103 BTs derived from SCID mouse blood. At experimental endpoints,
mice were sacriﬁced by exsanguination under terminal anesthesia.
For in vivo bioluminescence imaging, mice were injected with 150 mg/kg D-luciferin i.p., then
anesthetized using 2.5% (vol/vol) gaseous isoﬂurane (25). Five to 10 min after D-luciferin administration,
they were placed in an IVIS Lumina II system (Caliper Life Science), and images were acquired using
LivingImage v4.3. Exposure times varied between 30 s and 5 min, depending on signal intensity. After
imaging, mice were revived and returned to cages. For ex vivo imaging, mice were injected with
D-luciferin and sacriﬁced by exsanguination under terminal anesthesia 5 min later. They were then
perfused via the heart with 10 ml of 0.3 mg/ml D-luciferin in PBS. Organs and tissues were removed and
transferred to a petri dish in a standardized arrangement (Fig. 1C), soaked in 0.3 mg/ml D-luciferin in PBS,
and imaged using maximum detection settings (5 min exposure, large binning). The remaining animal
parts and carcass were checked for residual bioluminescent foci, also using maximum detection settings.
To estimate parasite burden in live mice, regions of interest (ROI) were drawn using LivingImage v4.3
to quantify bioluminescence as total ﬂux (photons/s), summed from dorsal and ventral images. The
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detection threshold for in vivo imaging was determined using control uninfected mice. To quantify
infection intensities in ex vivo tissues, individual ROIs were drawn to quantify bioluminescence expressed
as radiance (p/s/cm2/sr).
Drug treatment. Benznidazole was synthesized by Epichem Ltd. (Australia) and prepared for
administration at 10 mg/ml in 5% dimethyl sulfoxide (vol/vol)/95% hydroxypropyl methylcellulose
(HPMC) suspension vehicle (0.5% (wt/vol) hydroxypropyl methylcellulose, 0.5% (vol/vol) benzyl alcohol,
and 0.4% (vol/vol) Tween 80 in Milli-Q-water). Mice were treated at 100 mg/kg for 20 days by oral gavage
(35) (Fig. 1 for details).
Cardiac histomorphometric studies. Heart samples were ﬁxed in Glyo-Fixx for 24 h, dehydrated in
ethanol, cleared in Histo-Clear, and embedded in parafﬁn. Three-micron heart sections were stained with
hematoxylin and eosin (H&E) or Masson’s trichrome (MT). Images covering atrioventricular regions were
acquired with a camera (Leica DFC295) attached to a Leica DM3000 light-emitting diode (LED) micro-
scope. Images were digitalized for histomorphometric analysis using the Leica Application Suite v4.5
software. The base of the heart and major vessels were excluded because of inherently high collagen
content. The number of images required for accurate representative quantiﬁcation of the whole
myocardium was determined by stability analysis of measurements based on a range of ﬁelds, from a
minimum of 5 to a maximum of 20. An index of inﬂammatory cells was assessed by quantifying a
standardized test area of 6  104 m2 per image, acquired with a 40 objective. The number of
cells/image was determined from the average of 15 images/animal at 400 magniﬁcation, randomly
chosen, with samples stained with H&E. An increase in the number of cells compared with uninfected
controls was considered indicative of inﬂammation. An index of collagen type I, the most abundant form,
which accounts for 90% of total collagen in mammals, was assessed by quantifying a standardized test
area of 6  104 m2 per image, acquired with a 40 objective. The area in blue MT staining was
determined from an average of 15 randomly chosen images/animal, at 400 magniﬁcation. Increased
collagen content compared with that of uninfected controls was considered indicative of cardiac ﬁbrosis.
Statistics. Individual animals were used as the unit of analysis unless otherwise stated. Statistical
differences between groups were evaluated using a Kruskal-Wallis test with Dunn’s post hoc correction
in GraphPad Prism v.7.03. Differences of P  0.05 were considered signiﬁcant.
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